Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


02. June 2020 | 05:58 CET

Memphasys, Moderna, Paion - Investments in solutions with potential

  • Healthcare
Photo credits: pixabay.com

Biotech companies around the world employ scientists and physicians to study the causes of diseases. The research and development of medical products and solutions usually involves a large number of tests and takes a correspondingly long time. The longer and more extensive this process is, the more capital these companies require from investors. In the race to bring to market preparations or products that improve people's well-being or fulfill desires, the providers of solutions usually have great sales potential and investors may be bought out through a takeover.

time to read: 1 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Biological separation

Memphasys from Australia has developed a solution for parents with a desire to have children, which allows high-quality sperm to be biologically separated from the man's seminal fluid. The product from Memphasys is called FELIX and increases the chances of success of artificial insemination. The company thus serves a growth market, as more and more couples are deciding to start their professional career first when planning their lives. With increasing age, however, the chance of success of a natural pregnancy decreases and the advice of experts is sought.

In the second half of 2020, FELIX is to be launched in various countries around the globe. The biological separation process not only works with humans, but can also be used with mammals in the future - also a huge market, according to Alison Coutts Memphasys' market capitalization is currently AUD 52 million at AUD 0.07 per share. The shares are also traded in Germany.

Covid-19 vaccine hope

The US biotech company Moderna is in the public eye as it is working on a vaccine against Covid-19, and since the outbreak of the Corona Pandemic, the value of its shares has already risen by around 200%, and at USD 62 per share, its market value is over USD 23 billion. In a recent announcement, the company provided information on the development status. The mid-stage clinical trials have started with 600 patients. Moderna has been researching a vaccine candidate since March 2020 and people are hopeful that a vaccine will provide a way out of the Corona Crisis.

Approval for anaesthetics

The Paion shares are also hot at the moment. The company may receive approval for the anesthetic Remimazolam from the US Food and Drug Administration (FDA) in the coming months. "In 2020, Paion's focus will be on evaluating the European Phase III study in general anaesthesia, the regulatory approval process in the US, Europe and other regions, the development of the supply chain and commercial manufacturing of Remimazolam, as well as the market preparation and launch of Remimazolam in different territories," the company announced. Paion's most recent liquidity was approximately EUR 18 million and its share price of EUR 2.29 represents a market value of EUR 143 million.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

17. March 2021 | 07:25 CET | by Nico Popp

Fresenius SE, Q+M Dental Group, Siemens Healthineers: Where growth meets dividends

  • Healthcare

The back-and-forth surrounding AstraZeneca's vaccine has unsettled many people. But the discussion about extremely rare side effects also shows: Vaccines and drugs are subject to strict regulations and the healthcare system is strictly regulated. While pharmaceutical companies must always expect setbacks, especially in accelerated approval procedures, the situation is different for suppliers of medical technology or consumables. We present three stocks that are benefiting from rising healthcare spending.

Read

19. January 2021 | 10:50 CET | by Nico Popp

Pfizer, Q&M Dental Group, Johnson & Johnson: Where do profiteers of the pandemic lurk?

  • Healthcare

We all know that one's health is the most important thing. But from time to time, this truism slips out of focus. The pandemic has shown that neither fame nor money can protect you from getting sick. A big step toward being healthy, however, can be made by trusting in research. The development of vaccines in record time has shown how great the potential is in science and the pharmaceutical industry. New test methods are continually coming onto the market. Three shares show that there is money to be made on the stock market from these developments.

Read

12. January 2021 | 10:28 CET | by Carsten Mainitz

CureVac, Q&M Dental, Moderna - What you didn't know - really exciting!

  • Healthcare

The World Health Organization (WHO) recorded more than 235 Covid-19 vaccine projects worldwide since January 2020, but few projects make it across the finish line. Timing is a critical factor, and early entrants will divide the huge market among themselves. These include BioNTech/Pfizer, Moderna and AstraZeneca. Still in the "test phase" is Tübingen-based CureVac, which recently entered into a sales cooperation with Bayer. Information published yesterday is positive and suggests approval of the preparation by the beginning of the second quarter of 2021 at the latest. Away from vaccine manufacturers, other Corona profiteers exist with which investors can earn handsomely. Q&M Dental from Singapore is little known. Its subsidiary is one of nine government-approved Corona testing facilities. Also, Q&M supplies Asian neighboring countries with millions of its Corona testing. We inform you about the news and potentials of known and unknown players.

Read